Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects

No Thumbnail Available

Date

2021-11-02

Authors

Aldea, Mihaela
Lam, Laurent
Orillard, Emeline
Llacer Perez, Casilda
Saint-Ghislain, Mathilde
Gravis, Gwenaelle
Flechon, Aude
Roubaud, Guilhem
Barthelemy, Philippe
Ricci, Francesco

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Elsevier sci ltd
Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Background: Cabazitaxel was shown to improve overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) after abiraterone/enzalutamine and docetaxel failure, though benefit by the presence of DNA damage repair (DDR) defects is unknown. With the advent of poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) in partially overlapping indications with cabazitaxel, we aimed to determine cabazitaxel activity in men with mCRPC according to their DDR status.Methods: This is a retrospective multicenter study that enrolled patients with mCRPC treated with cabazitaxel who had undergone DDR tumour tissue profiling. Patients with at least one deleterious germline or somatic alterations were considered DDR positive (DDR+). Each DDR + patient has been matched with a DDR negative (DDR-) from the same institution who underwent the same test. An exploratory cohort of patients found to be DDR + by liquid biopsy was also included. Prostate specific antigen (PSA) decline >= 50% (PSA50), PSA progression-free survival (PFS, PSA-PFS), radiographic PFS (rPFS), clinical PFS or radiographic PFS (c/rPFS) and OS were evaluated.Results: Among 190 men (95 DDR+, 95 DDR-) with tissue sequencing, PSA50 was achieved with cabazitaxel in 29/92 (32%) and 33/92 (36%) in patients with DDR+ and DDR(P = 0.64). The median rPFS was 5.33 months [9 5%CI 4.34-7.04] versus 5.75 months [95%CI 4.67-7.27] (P = 0.55). The median OS was 15.4 months [95%CI 12.16-26.6] and 11.5 months [95%CI 9.76-14.4] (P = 0.036), respectively. No PSA50 responses on cabazitaxel were observed in BRCA1/2 patients previously treated with PARPi (n = 10). Similar outcomes with cabazitaxel were observed in the liquid biopsy cohort (n = 63 DDR+).Conclusions: Our study suggests that cabazitaxel is active in patients with mCRPC regardless of their DDR status, although its activity in men pretreated with a PARPi may be lower. (C) 2021 Elsevier Ltd. All rights reserved.

Description

MeSH Terms

DeCS Terms

CIE Terms

Keywords

DNA damage repair, BRCA, Cabazitaxel, PARP inhibitors, mCRPC, Treatment outcomes, Gene-mutations, Phase-iii

Citation